November 22, 2013

Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial

Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints

Sarilumab is the First Fully-Human Monoclonal Antibody Directed Against the Interleukin-6 Receptor (IL-6R)

 

Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints

Paris, France and Tarrytown, NY – November 22, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the SARIL- RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy, sarilumab (the first fully-human anti-IL-6R monoclonal antibody) treatment in combination with MTX improved disease signs and symptoms as well as physical function, and inhibited progression of joint damage.